BUSINESS
Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s
CNBC BusinessFriday, October 2, 2026 at 5:55 PM
RedScroll Brief
Eli Lilly and Novo are developing new amylin drugs that serve as another biological lever to pull in treating obesity and diabetes.
RedScroll Signal
- Impact
- High
- Category
- Business
- Market relevance
- High
- Why it matters
- Corporate and market moves reprice risk and reveal where power and cash are concentrating. Eli Lilly and Novo are developing new amylin drugs that serve as another biological lever to pull in treating obesity and diabetes. Investors will watch earnings, rates, and competitive positioning connected to Why Lilly and Novo.
Desk copy
RedScroll Briefing
Extractive editorial brief — not a reprint of the original
What happened
Eli Lilly and Novo are developing new amylin drugs that serve as another biological lever to pull in treating obesity and diabetes.
Why it matters
Corporate and market moves reprice risk and reveal where power and cash are concentrating.
Background
CNBC Business reported on this under business. RedScroll surfaces the signal with an extractive brief — not a reprint of the original article. Read the source for full reporting.
Timeline
CNBC Business published: Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s
Story is in today’s RedScroll edition. Follow the original source for updates.
Economic impact
Investors will watch earnings, rates, and competitive positioning connected to Why Lilly and Novo.
More on
Related stories
- El Salvador Troops Killed in Haiti Blast After Rescue Deployment
Bloomberg MarketsBUSINESS
- Trump Says Huang Should Return to Nvidia After ‘Big Apology’
Bloomberg MarketsBUSINESS
- Anthropic shares fall a day after blockbuster opening
BBC BusinessBUSINESS
- Traders now see little chance of a Fed rate hike in October after weak jobs report
CNBC FinanceBUSINESS
- Anthropic soars, but it may soon be back, cap in hand
The Economist BusinessBUSINESS
- You’re not sending an email. You’re training a model
The Economist BusinessBUSINESS
Source
CNBC Business
Original reporting by CNBC Business. RedScroll provides an extractive briefing only.